MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$19,892K
Free Cash flow
-$19,910K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Share-based compensation expense
Other
Right-of-use assets
Others
Negative Cash Flow Breakdown
General and administrative
Deferred revenue
Lease liabilities
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
2,959
2,061
7,196
17,152
Total research and development
17,515
21,527
24,476
87,736
General and administrative
10,989
9,465
14,027
10,398
Other
-1,760
-1,967
-2,228
-3,063
Net loss
-23,785
-26,964
-29,079
-13,448
Depreciation and amortization
643
658
682
763
Share-based compensation expense
4,231
4,325
6,817
5,729
Gain on sale of equipment
18
34
-
-
Foreign currency transaction loss
-7
-1
-63
-170
Impairment of right-of-use assets
-
-
1,897
-
Loss on disposal of property and equipment
-72
-
-
-
Accounts receivable
470
-4,221
-2,387
-9,253
Prepaid expense and other assets
-299
-809
-916
57
Right-of-use assets
-665
-658
-861
-955
Accounts payable
321
-142
-1,343
-5,045
Accrued liabilities
173
-1,233
4,453
-5,417
Deferred revenue
-1,334
-636
-2,800
-8,986
Lease liabilities
-714
-1,104
-1,081
-1,068
Net cash used in operating activities
-19,910
-19,441
-16,227
-17,151
Acquisition of property and equipment
0
0
-88
181
Proceeds from sale of equipment
18
34
-
-
Net cash used in investing activities
18
34
88
-181
Proceeds from exercise of stock options
0
16
0
640
Proceeds from issuance of common stock under equity plans
-
-
0
585
Proceeds from issuance of common stock, net of issuance costs
-
-
11,688
-
Proceeds from debt
0
0
0
0
Payments on debt obligations
0
-
0
0
Net cash provided by financing activities
0
16
11,688
1,225
Net decrease in cash, cash equivalents and restricted cash
-19,892
-19,391
-4,451
-16,107
Cash, cash equivalents and restricted cash at beginning of the period
213,403
232,794
237,245
293,913
Cash, cash equivalents and restricted cash at end of the period
193,511
213,403
232,794
237,245
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
equipment
$18K
Net cash used in
investing activities
$18K
(113.14%↑ Y/Y)
Net decrease in
cash, cash...
-$19,892K
(50.96%↑ Y/Y)
Canceled cashflow
$18K
Share-based compensation
expense
$4,231K
(-67.10%↓ Y/Y)
Right-of-use assets
-$665K
(64.63%↑ Y/Y)
Depreciation and
amortization
$643K
(-59.30%↓ Y/Y)
Accounts payable
$321K
(-90.64%↓ Y/Y)
Prepaid expense and
other assets
-$299K
(92.79%↑ Y/Y)
Accrued liabilities
$173K
(101.21%↑ Y/Y)
Loss on disposal of
property and equipment
-$72K
Foreign currency
transaction loss
-$7K
(95.30%↑ Y/Y)
Net cash used in
operating activities
-$19,910K
(51.31%↑ Y/Y)
Canceled cashflow
$6,411K
Revenue
$2,959K
(-94.87%↓ Y/Y)
Other
-$1,760K
(66.06%↑ Y/Y)
Net loss
-$23,785K
(-2.27%↓ Y/Y)
Canceled cashflow
$4,719K
Deferred revenue
-$1,334K
(88.96%↑ Y/Y)
Lease liabilities
-$714K
(65.42%↑ Y/Y)
Accounts receivable
$470K
(-96.45%↓ Y/Y)
Gain on sale of
equipment
$18K
Total research and
development
$17,515K
General and
administrative
$10,989K
(-49.25%↓ Y/Y)
Buy us a coffee
Arcturus Therapeutics Holdings Inc. (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT)